Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CSTL

Castle Biosciences Inc

Dec 17 • 04:00PM ET

39.66

+0.61 1.56 %

Healthcare • Diagnostics & Research • USA • NASD

Dec 17, 7:05 AMCastle Biosciences says a Nature Communications study shows its DecisionDx-UM plus PRAME outperforms NGS mutation analysis in predicting survival outcomes in uveal melanoma, bolstering the tests' clinical utility and potential adoption.

Peers: GH EXAS FLGT CDNA MYGN NTRA QDEL DGX ILMN TXG

| Held by: VTI IWM VXF IWN IBB DFAT VTWO SCHA BSVO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.45	Insider Own	2.77%	Shs Outstand	29.16M	Perf Week	4.31%
Market Cap	1.16B	Forward P/E	-	EPS next Y	-1.42	Insider Trans	-21.45%	Shs Float	28.38M	Perf Month	16.82%
Enterprise Value	907.22M	PEG	-	EPS next Q	-0.34	Inst Own	91.27%	Short Float	6.47%	Perf Quarter	69.05%
Income	-12.24M	P/S	3.37	EPS this Y	-281.13%	Inst Trans	-0.32%	Short Ratio	4.53	Perf Half Y	109.73%
Sales	343.53M	P/B	2.48	EPS next Y	-26.64%	ROA	-2.27%	Short Interest	1.84M	Perf YTD	48.82%
Book/sh	16.02	P/C	4.03	EPS next 5Y	-	ROE	-2.69%	52W High	40.61 -2.34%	Perf Year	37.37%
Cash/sh	9.85	P/FCF	36.11	EPS past 3/5Y	- -	ROIC	-2.43%	52W Low	14.59 171.83%	Perf 3Y	71.91%
Dividend Est.	-	EV/EBITDA	115.86	Sales past 3/5Y	52.25% 44.97%	Gross Margin	68.58%	Volatility	3.86% 3.97%	Perf 5Y	-32.96%
Dividend TTM	-	EV/Sales	2.64	EPS Y/Y TTM	-295.52%	Oper. Margin	-10.17%	ATR (14)	1.43	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.31	Sales Y/Y TTM	10.15%	Profit Margin	-3.56%	RSI (14)	72.26	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	6.47	EPS Q/Q	-122.28%	SMA20	2.88%	Beta	1.06	Target Price	39.25
Payout	0.00%	Debt/Eq	0.08	Sales Q/Q	-3.19%	SMA50	24.60%	Rel Volume	0.79	Prev Close	39.05
Employees	761	LT Debt/Eq	0.08	Earnings	Nov 03 AMC	SMA200	74.89%	Avg Volume	405.27K	Price	39.66
IPO	Jul 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	96.16% 16.79%	Trades		Volume	319,842	Change	1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

Dec-17-25 10:29AM	GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment (Zacks)
09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
08:43AM	FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug (Zacks)
07:00AM	Landmark Study Shows Combination of Castle Biosciences' DecisionDx-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma (GlobeNewswire)
Dec-16-25 10:43AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Zacks)
10:10AM	Loading…
10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks)
09:55AM	CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike (Zacks)
Dec-15-25 10:27AM	GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU (Zacks)
Dec-12-25 10:08AM	GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea (Zacks)
07:00AM	Systematic Review and Meta-Analysis Confirms TissueCypher Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer (GlobeNewswire)
Dec-11-25 11:03AM	GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer (Zacks)
09:40AM	Are Medical Stocks Lagging Cronos Group (CRON) This Year? (Zacks)
Dec-10-25 09:43AM	TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia (Zacks)
Dec-09-25 10:43AM	KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study (Zacks)
10:24AM	Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date (Zacks)
07:00AM	Loading…
07:00AM	Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma (GlobeNewswire)
Dec-08-25 08:55AM	Here's Why 'Trend' Investors Would Love Betting on Castle Biosciences (CSTL) (Zacks)
Nov-25-25 10:45AM	SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria (Zacks)
Nov-24-25 10:50AM	FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer (Zacks)
Nov-21-25 08:55AM	Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +6.05%
Nov-20-25 09:14AM	ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal (Zacks)
08:48AM	5 Stocks With Recent Price Strength Amid Wall Street Volatility (Zacks)
Nov-19-25 10:59AM	Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri (Zacks)
Nov-18-25 10:36AM	Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal (Zacks)
Nov-17-25 07:00AM	Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year (GlobeNewswire)
03:49AM	Zacks.com featured highlights include Perimeter Solutions, Interface, Castle Biosciences and Great Lakes Dredge & Dock (Zacks)
Nov-14-25 07:39AM	Forget the Fed, Bet on These 4 Stocks With Increasing Cash Flows (Zacks)
07:00AM	New Data Confirms Performance of DecisionDx-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity (GlobeNewswire)
Nov-12-25 06:02AM	Zacks.com featured highlights include Castle Biosciences, Perimeter Solutions, South Atlantic Bancshares and Astronics (Zacks)
Nov-11-25 07:00AM	Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
01:43AM	Loading…
01:43AM	4 Stocks With Recent Price Strength to Enhance Your Portfolio (Zacks)
Nov-05-25 12:36PM	Recent Price Trend in Castle Biosciences (CSTL) is Your Friend, Here's Why (Zacks) +6.13%
Nov-04-25 12:02AM	Castle Biosciences Inc (CSTL) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) +21.70%
Nov-03-25 06:05PM	Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Castle Biosciences Reports Third Quarter 2025 Results (GlobeNewswire)
04:05PM	Castle Biosciences Launches AdvanceAD-Tx to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Oct-31-25 09:29AM	Castle Biosciences Inc (CSTL) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +5.33%
03:20AM	Zacks.com featured highlights include RadNet, Mission Produce, Castle Biosciences and FreightCar America (Zacks)
Oct-30-25 12:01PM	Forget Profit, Pick These 4 Stocks With Increasing Cash Flows (Zacks)
07:40AM	Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-28-25 10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy? (Zacks)
07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 10:00AM	Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-26-25 03:05PM	New Data at American College of Gastroenterology Annual Meeting Show TissueCypher Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus (GlobeNewswire)
Oct-24-25 04:05AM	New Analysis of 13,560 Patients Demonstrates DecisionDx-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-23-25 10:27AM	ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition (Zacks)
09:55AM	How Much Upside is Left in Castle Biosciences (CSTL)? Wall Street Analysts Think 50.08% (Zacks)
Oct-21-25 12:00PM	What Makes Castle Biosciences (CSTL) a New Strong Buy Stock (Zacks)
Oct-13-25 07:00AM	Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025 (GlobeNewswire)
Oct-01-25 04:30PM	Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine (GlobeNewswire)
Sep-23-25 07:00AM	Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award (GlobeNewswire)
Sep-17-25 07:00AM	Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025 (GlobeNewswire)
Sep-09-25 07:00AM	New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions (GlobeNewswire)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire) +5.30%
Aug-25-25 07:00AM	New Evidence Published Supporting Use of DecisionDx-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Aug-21-25 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-25 03:04AM	Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... (GuruFocus.com) +32.83%
Aug-04-25 05:20PM	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:05PM	Castle Biosciences Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-01-25 05:11AM	New Strong Sell Stocks for August 1st (Zacks)
Jul-29-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
07:00AM	Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-28-25 10:00AM	Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline (Zacks)
Jul-25-25 07:00AM	Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal (GlobeNewswire)
Jul-23-25 07:00AM	FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx-Melanoma Test (GlobeNewswire)
Jul-17-25 07:00AM	Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture (GlobeNewswire) -6.91%
Jul-14-25 07:00AM	Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 (GlobeNewswire)
Jun-19-25 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 04:30PM	Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases (GlobeNewswire)
Jun-11-25 07:00AM	Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention (GlobeNewswire)
Jun-04-25 07:00AM	Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards (GlobeNewswire)
May-29-25 11:56PM	Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 (Insider Monkey)
04:30PM	New Data at ASCO 2025 Affirms DecisionDx-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes (GlobeNewswire)
May-21-25 07:00AM	Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-25 07:00AM	Real-World Study Confirms Long-Term Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result (GlobeNewswire)
May-07-25 07:00AM	Castle Biosciences Celebrates Skin Cancer Awareness Month (GlobeNewswire)
May-06-25 11:15AM	Q1 2025 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -11.36%
03:07AM	Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
May-05-25 05:15PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Castle Biosciences Reports First Quarter 2025 Results (GlobeNewswire)
04:05PM	Castle Biosciences to Acquire Previse (GlobeNewswire)
May-02-25 04:30PM	New Data at DDW 2025 Further Demonstrates the TissueCypher Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer (GlobeNewswire)
09:30AM	Castle Biosciences Inc (CSTL) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 05:00PM	New Study Shows Castle Biosciences' DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity (GlobeNewswire)
07:05AM	GSK (GSK) Q1 Earnings Surpass Estimates (Zacks)
Apr-28-25 07:00AM	DecisionDx -Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma (GlobeNewswire)
Apr-25-25 04:15PM	New Data at AACR Annual Meeting Highlights Use of DecisionDx -Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis (GlobeNewswire)
Apr-14-25 07:10PM	Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern (Seeking Alpha) +5.83%
07:00AM	Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 (GlobeNewswire)
Apr-08-25 07:00AM	Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships (GlobeNewswire)
Apr-07-25 07:00AM	Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year (GlobeNewswire)
Apr-03-25 07:00AM	Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx-Melanoma Test (GlobeNewswire)
Apr-01-25 04:30PM	Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx -Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma (GlobeNewswire)
Mar-28-25 04:15PM	Castle Biosciences' DecisionDx -SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups (GlobeNewswire)
Mar-07-25 07:00AM	New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio (Business Wire)
Feb-28-25 11:11AM	Q4 2024 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -14.24%
02:37AM	Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-27-25 06:15PM	Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results (Business Wire)
Feb-26-25 07:58AM	What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings (GuruFocus.com)

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kristen M. Oelschlager	Officer	Dec 17 '25	Proposed Sale	39.05	14,888	581,376		Dec 17 04:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '25	Sale	38.78	19,525	757,099	47,690	Dec 17 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 16 '25	Sale	38.55	12,821	494,301	34,869	Dec 17 04:20 PM
Derek Maetzold	Officer	Dec 15 '25	Proposed Sale	38.88	33,685	1,309,673		Dec 15 06:21 PM
Juvenal Tobin W	Chief Commercial Officer	Dec 11 '25	Sale	37.48	13,200	494,736	86,825	Dec 15 04:09 PM
Stokes Frank	Chief Financial Officer	Dec 11 '25	Sale	37.45	4,496	168,375	50,326	Dec 15 04:08 PM
TOBIN JUVENAL	Officer	Dec 11 '25	Proposed Sale	37.48	13,200	494,675		Dec 11 04:30 PM
FRANKLIN M. STOKES	Officer	Dec 11 '25	Proposed Sale	37.45	4,496	168,375		Dec 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '25	Sale	40.03	1,339	53,600	37,547	Dec 08 04:28 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 02 '25	Sale	39.23	2,678	105,058	38,886	Dec 04 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 26 '25	Sale	40.09	4,258	170,703	41,564	Dec 01 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 25 '25	Sale	40.05	5,115	204,851	45,822	Nov 26 02:58 PM
Derek Maetzold	Officer	Nov 25 '25	Proposed Sale	39.93	10,712	427,730		Nov 25 05:11 PM
TOBIN JUVENAL	Officer	Nov 24 '25	Proposed Sale	37.88	1,301	49,282		Nov 24 04:28 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 20 '25	Option Exercise	3.38	4,693	15,862	89,288	Nov 24 04:24 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 20 '25	Sale	35.58	4,693	166,977	84,595	Nov 24 04:24 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 18 '25	Sale	34.02	2,678	91,106	50,937	Nov 20 04:07 PM
Stokes Frank	Chief Financial Officer	Nov 11 '25	Sale	35.08	5,388	189,011	43,328	Nov 13 04:08 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 11 '25	Sale	35.39	500	17,695	84,027	Nov 13 04:08 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 12 '25	Sale	35.40	200	7,080	83,827	Nov 13 04:08 PM
Oelschlager Kristen M	Chief Operating Officer	Nov 11 '25	Sale	35.10	18,932	664,513	12,323	Nov 13 04:07 PM
Kristen M. Oelschlager	Officer	Nov 11 '25	Proposed Sale	34.74	18,932	657,698		Nov 12 09:32 AM
TOBIN JUVENAL	Officer	Nov 11 '25	Proposed Sale	34.74	5,393	187,353		Nov 12 07:03 AM
FRANKLIN STOKES	Officer	Nov 11 '25	Proposed Sale	34.74	5,388	187,179		Nov 12 06:58 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 04 '25	Sale	30.44	6,695	203,782	56,293	Nov 06 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 05 '25	Sale	31.85	2,678	85,297	53,615	Nov 06 04:08 PM
Oelschlager Kristen M	Chief Operating Officer	Oct 31 '25	Sale	25.04	12,678	317,457	27,569	Nov 04 08:56 PM
Derek Maetzold	Officer	Nov 04 '25	Proposed Sale	31.63	13,390	423,526		Nov 04 04:53 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 20 '25	Sale	22.44	1,339	30,047	62,988	Oct 23 09:30 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 02 '25	Sale	22.58	1,339	30,235	64,327	Oct 06 04:11 PM
Derek Maetzold	Officer	Oct 02 '25	Proposed Sale	22.23	4,017	89,298		Oct 02 05:17 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 17 '25	Sale	21.97	1,339	29,419	65,666	Sep 19 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 02 '25	Sale	23.93	1,339	32,042	67,005	Sep 04 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	22.02	12,677	279,135	141,116	Aug 29 04:04 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 27 '25	Sale	21.69	18,007	390,572	153,793	Aug 29 04:04 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	18,007	384,449		Aug 27 06:15 PM
Kristen M. Oelschlager	Officer	Aug 27 '25	Proposed Sale	21.35	25,355	541,329		Aug 27 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 15 '25	Sale	20.04	1,339	26,834	68,344	Aug 19 04:04 PM
Derek Maetzold	Officer	Aug 15 '25	Proposed Sale	20.09	4,017	80,702		Aug 15 05:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 13 '25	Sale	19.50	43,019	839,043	69,683	Aug 15 04:14 PM
Derek Maetzold	Officer	Aug 13 '25	Proposed Sale	19.41	43,019	834,999		Aug 13 05:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 08 '25	Option Exercise	0.00	66,991	0	136,674	Aug 12 04:32 PM
Stokes Frank	Chief Financial Officer	Aug 08 '25	Option Exercise	0.00	9,744	0	53,072	Aug 12 04:31 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	174,604	Aug 12 04:31 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 08 '25	Option Exercise	0.00	10,640	0	88,821	Aug 12 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	17,632	357,930	3,615	Jul 01 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 27 '25	Sale	20.30	4,944	100,363	69,683	Jul 01 04:05 PM
Derek Maetzold	Officer	Jun 27 '25	Proposed Sale	20.35	16,932	344,566		Jun 27 06:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	4,408	94,851	4,275	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '25	Sale	21.52	1,236	26,596	74,627	Apr 23 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	3,647	73,739	4,440	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 09 '25	Sale	20.22	1,023	20,684	75,863	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	761	15,243	4,577	Apr 10 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 08 '25	Sale	20.03	213	4,266	76,886	Apr 10 04:07 PM
Derek Maetzold	Officer	Apr 08 '25	Proposed Sale	18.60	16,932	314,935		Apr 08 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '25	Sale	20.30	4,408	89,482	4,605	Mar 28 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 26 '25	Sale	20.30	1,236	25,091	77,099	Mar 28 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '25	Sale	20.12	22,639	455,426	80,465	Mar 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '25	Sale	20.12	4,408	88,674	4,770	Mar 11 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 10 '25	Sale	19.52	2,130	41,573	78,335	Mar 11 04:07 PM
Derek Maetzold	Officer	Mar 07 '25	Proposed Sale	20.21	34,821	703,732		Mar 07 04:57 PM
Derek Maetzold	Officer	Mar 04 '25	Proposed Sale	22.23	5,687	126,422		Mar 04 05:28 PM
Stokes Frank	Chief Financial Officer	Feb 20 '25	Sale	26.70	8,046	214,828	35,319	Feb 24 04:23 PM
BRADBURY DANIEL	Director	Feb 05 '25	Sale	28.17	7,867	221,637	0	Feb 07 04:12 PM
Daniel Bradbury	Officer	Feb 05 '25	Proposed Sale	28.12	7,867	221,220		Feb 05 04:25 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 13 '25	Sale	28.03	1,579	44,262	5,104	Jan 15 04:57 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 13 '25	Sale	28.03	986	27,641	80,818	Jan 15 04:57 PM
BRADBURY DANIEL	Director	Jan 06 '25	Sale	29.14	7,867	229,226	1,425	Jan 08 06:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '25	Sale	29.62	4,343	128,637	5,291	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 06 '25	Sale	29.62	2,715	80,412	82,047	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 07 '25	Sale	30.14	388	11,694	5,254	Jan 08 06:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jan 07 '25	Sale	30.14	243	7,324	81,804	Jan 08 06:18 PM
Juvenal Tobin W	Chief Commercial Officer	Jan 06 '25	Sale	30.00	2,230	66,900	69,943	Jan 08 06:17 PM
TOBIN JUVENAL	Officer	Jan 06 '25	Proposed Sale	28.61	2,230	63,800		Jan 06 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CSTL

Castle Biosciences Inc

Upgrade your FINVIZ experience